Streamline your pricing and reimbursement data management and analysis
Your Complete Market Access RepositoryAll the market access records you need are located in a single, interoperable repository. Effortlessly share information across your organization via a secure and consistent workflow using our integrated platform. Create different user profiles to tailor your Market Access Radar (MAR) repository. Receive further details with analysis from our local experts (personal assistance during service). Data is sourced and gathered from over 50 countries.
Spend your time on the pricing and reimbursement (P&R) strategy, not searching for relevant information
The intuitive interface guides users in visualizing data flow and analysis of P&R information. Deliver reproducible, quality results with automated workflows that can be saved, locked, customized, reused, and shared during your organization.
Sign up for daily reports from Market Access Radar!
Market Access Radar Daily Report
- Daily updates on critical market access news from our expert-curated international scan
- Over 600 sources scanned daily covering more than 50 countries
- Payer and HTA decisionmaker actions and policy changes around the world with access directly to original sources
- Daily email update directly to your inbox requiring no login
Supporting efficient P&R workflows
Market Access Radar (MAR) repository was created to provide you with quick and easy access to the most important market access related information. Insights presented in MAR follow an easy-to-follow layout to bring the most relevant data directly to you. We gather the latest reimbursement recommendations and information on financing from public funds announced by Ministries of Health (MOH) and Health Technology Assessment (HTA) agencies and changes in legal provisions regulating the financing of health technologies from public funds.
Compliant, integrated P&R records
News on drug safety, new marketing authorizations, variations in registered and reimbursed indications published by EMA, HMA, FDA, MHRA, Ministries of Health and other national institutions responsible for registration and safety of drugs and other valuable information which may impact reimbursement, published in mass media and relevant press.
A Look into Market Access Radar (MAR)
Get the data you need when you need it most. Curated by experts, Certara’s Market Access Radar (MAR) is the industry preferred one-stop-shop for the latest and most up-to-date market access-related news and reports. Explore our collection of videos for a look into MAR.
- Customer request & example using MAR – Certara experts share an example of how we use MAR to fulfill a customer request.
- Client-specific use case example – This video shows how we used MAR to provide continuous monitoring of data to fulfil a specific client request.
- Why is MAR so valuable? – Hear from a Certara expert on why MAR is so valuable.
- MAR Dedicated Feature – Develop a specific view over time – A quick look into one of MAR’s dedicated features on how to develop a customized view.
Roman Casciano is a Senior Vice President within Certara’s Evidence and Access group. As an applied health economist and market access strategist, Roman has personally led hundreds of engagements in the global market access, HEOR and real-world evidence context related to product value demonstration and has deep experience in both formal and informal exchanges with payers and HTA bodies.
Elvira Müller is Vice President within Certara’s Evidence & Access group, responsible for HTA and Evidence Development while managing Certara’s consulting team base in Germany. Besides numerous HTA engagements, she has substantial experience in EUnetHTA collaboration as well as in European Joint Clinical Assessments (JCA) and Joint Scientific Consultation (JSC). She has 20+ years of experience in global market access, applying her senior expertise in providing high-quality scientific advice to optimize the value of pharmaceuticals and medical technologies. Elvira holds an MSc and PhD in Biology and Toxicology from Würzburg University and an MPH from Ulm University.
Jacek Walczak co-founded Arcana Institute in Poland and holds the position of Vice President, EU Market Access at Certara in Poland. He has over 20 years of experience in systematic reviews, participating in over 200 HTA/market access projects and heading three international projects for the Leonardo Program. He has also served as an advisor for the Drug Policy Department at the Ministry of Health, co-authored Polish HTA guidelines and was an expert at the National Center for Quality Assessment. Jacek is a qualified orthopedic surgeon (Collegium Medicum of Jagiellonian University).
Roman Casciano is a Senior Vice President within Certara’s Evidence and Access group. As an applied health economist and market access strategist, Roman has personally led hundreds of engagements in the global market access, HEOR and real-world evidence context related to product value demonstration and has deep experience in both formal and informal exchanges with payers and HTA bodies.
Elvira Müller is Vice President within Certara’s Evidence & Access group, responsible for HTA and Evidence Development while managing Certara’s consulting team base in Germany. Besides numerous HTA engagements, she has substantial experience in EUnetHTA collaboration as well as in European Joint Clinical Assessments (JCA) and Joint Scientific Consultation (JSC). She has 20+ years of experience in global market access, applying her senior expertise in providing high-quality scientific advice to optimize the value of pharmaceuticals and medical technologies. Elvira holds an MSc and PhD in Biology and Toxicology from Würzburg University and an MPH from Ulm University.
Jacek Walczak co-founded Arcana Institute in Poland and holds the position of Vice President, EU Market Access at Certara in Poland. He has over 20 years of experience in systematic reviews, participating in over 200 HTA/market access projects and heading three international projects for the Leonardo Program. He has also served as an advisor for the Drug Policy Department at the Ministry of Health, co-authored Polish HTA guidelines and was an expert at the National Center for Quality Assessment. Jacek is a qualified orthopedic surgeon (Collegium Medicum of Jagiellonian University).